{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(22)"],"submitter":["Ammann NL"],"pubmed_abstract":["Immune checkpoint inhibition (ICI) has yielded remarkable results in prolonging survival of metastatic melanoma patients but only a subset of individuals treated respond to therapy. Success of ICI treatment appears to depend on the number of tumor-infiltrating effector T-cells, which are known to be influenced by activated eosinophils. To verify the co-occurrence of activated eosinophils and T-cells in melanoma, immunofluorescence was performed in 285 primary or metastatic tumor tissue specimens from 118 patients. Moreover, eosinophil counts and activity markers such as eosinophil cationic protein (ECP) and eosinophil peroxidase (EPX) were measured in the serum before therapy start and before the 4th infusion of ICI in 45 metastatic unresected melanoma patients. We observed a positive corr"],"journal":["Cancers"],"pagination":["5676"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9688620"],"repository":["biostudies-literature"],"pubmed_title":["Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma."],"pmcid":["PMC9688620"],"pubmed_authors":["Ammann NL","Kott J","Mess C","Geidel G","Utikal J","Bauer AT","Stadler JC","Schwietzer YF","Pantel K","Schneider SW","Gebhardt C"],"additional_accession":[]},"is_claimable":false,"name":"Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma.","description":"Immune checkpoint inhibition (ICI) has yielded remarkable results in prolonging survival of metastatic melanoma patients but only a subset of individuals treated respond to therapy. Success of ICI treatment appears to depend on the number of tumor-infiltrating effector T-cells, which are known to be influenced by activated eosinophils. To verify the co-occurrence of activated eosinophils and T-cells in melanoma, immunofluorescence was performed in 285 primary or metastatic tumor tissue specimens from 118 patients. Moreover, eosinophil counts and activity markers such as eosinophil cationic protein (ECP) and eosinophil peroxidase (EPX) were measured in the serum before therapy start and before the 4th infusion of ICI in 45 metastatic unresected melanoma patients. We observed a positive corr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T13:28:14.938Z","creation":"2025-04-04T13:28:14.938Z"},"accession":"S-EPMC9688620","cross_references":{"pubmed":["36428768"],"doi":["10.3390/cancers14225676"]}}